DOCSLIB.ORG

Products With

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Products With ® 伊 域 化 學（香 藥 香 港） 業 港有 有 限 限 公 公 司 司 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD Rm 1006, 10/F, Hewlett Centre, Tel: (852) 25412772 (4 lines) No. 52-54, Hoi Yuen Road, Fax: (852) 25423444 / 25420530 / 21912858 Kwun Tong, E-mail: [email protected] YICKYICK----VICVICVICVIC 伊域伊域伊域 Kowloon, Hong Kong. Site: http://www.yickvic.com GMP Products Product Code CAS Product Name SPI-4425BC 147027-10-9 (2R,5S)-5-(4-AMINO-2-OXO-1(2H)-PYRIMIDINYL)-1,3-OXATHIOLANE-2-CARBOXYLIC ACID (1R,2S,5R)-5-METHYL-2-(1-METHYLETHYL)CYCLOHEXYL ESTER SPI-4425AB 147126-75-8 (2S,5R)-5-(4-AMINO-5-FLUORO-2-OXO-1(2H)-PYRIMIDINYL)-1,3-OXATHIOLANE-2-CARBOXYLIC ACID (1R,2S,5R)-5-METHYL-2-(1-METHYLETHYL)CYCLOHEXYL ESTER MIS-7072 25442-42-6 2,3'-ANHYDRO-1-(2-DEOXY-5-O-TRITYL-BETA-D-THREO-PENTOFURANOSYL)THYMINE PH-1231A 59-52-9 2,3-DIMERCAPTO-1-PROPANOL SPI-1783B 86404-63-9 2,4-DIFLUORO-ALPHA-(1H-1,2,4-TRIAZOLYL)ACETOPHENONE 863867-75-6 ? SPI-2152BA 26046-90-2 3-(METHYLSELENO)-L-ALANINE SPI-4402BA 181289-15-6 3-CARBAMOYLMETHYL-5-METHYLHEXANOIC ACID 185815-61-6 ((R)-ISOMER) SPI-2644AC 28783-41-7 4,5,6,7-TETRAHYDROTHIENO[3,2-C]PYRIDINE HYDROCHLORIDE MIS-0555 114772-55-3 4'-[(2-BUTYL-4-CHLORO-5-HYDROXYMETHYL-1H-IMIDAZOL-1-YL)METHYL]-1,1'-BIPHENYL-2-CARBONITRILE PH-0607 56-12-2 4-AMINOBUTYRIC ACID PH-0874 56-91-7 4-AMINOMETHYLBENZOIC ACID SPI-2486B 114772-54-2 4'-BROMOMETHYL-2-CYANOBIPHENYL SPI-1277A 134-83-8 4-CHLOROBENZHYDRYL CHLORIDE Copyright © 2013 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Page 1 of 38 Product Code CAS Product Name PH-0757 502-85-2 4-HYDROXYBUTYRIC ACID SODIUM SALT SPI-2652CB 102625-64-9 5-(DIFLUOROMETHOXY)-2-{[(3,4-DIMETHOXYPYRIDIN-2-YL)METHYL]THIO}-1H-BENZIMIDAZOLE PH-0404 51-21-8 5-FLUOROURACIL PH-2045BA 71751-41-2 ABAMECTIN PH-0863A 59-66-5 ACETAZOLAMIDE CC-1478AA 64-19-7 ACETIC ACID PH-1755A 546-88-3 ACETOHYDROXAMIC ACID PH-1194D 573-20-6 ACETOMENAPHTHONE PH-4799A 55079-83-9 ACITRETIN SPI-4650EC 8048-52-0 ACRIFLAVINE 65589-70-0 (UNSPECIFIED RATIO) 68518-47-8 (UNSPECIFIED RATIO) PH-1809A 59277-89-3 ACYCLOVIR SPI-1912HB 34369-07-8 ADENOSINE TRIPHOSPHATE DISODIUM HYDRATE 51963-61-2 (TRIHYDRATE) SPI-1912D 1687-51-0 ADENOSINE-3',5'-CYCLIC MONOPHOSPHATE PH-0541A 51-43-4 ADRENALINE PH-0870B 69-81-8 ADRENOCHROME SEMICARBAZONE PH-1411A 54965-21-8 ALBENDAZOLE PH-1751 9006-52-4 ALBUMIN TANNATE PH-3869C 129318-43-0 ALENDRONATE SODIUM,ANHYDROUS PH-3869B 121268-17-5 ALENDRONATE SODIUM,TRIHYDRATE PH-1412AA 97-59-6 ALLANTOIN PH-3177AA 539-86-6 ALLICIN PH-1825F 302-79-4 ALL-TRANS-RETINOIC ACID ® Copyright © 2013 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 2 of 38 Product Code CAS Product Name PH-4624 29608-49-9 ALMITRINE DIMESYLATE PH-2318A 2883-98-9 ALPHA-ASARONE PH-1416 28981-97-7 ALPRAZOLAM PH-0531B 14613-01-5 ALUFIBRATE 24818-79-9 PH-1419 21645-51-2 ALUMINIUM HYDROXIDE PH-0234B 665-66-7 AMANTADINE HYDROCHLORIDE PH-1963B 15942-05-9 ? AMBROXOL HYDROCHLORIDE 23828-92-4 PH-1420 37517-28-5 AMIKACIN DIHYDRATE PH-1418 39831-55-5 AMIKACIN SULFATE PH-0871 60-32-2 AMINOCAPROIC ACID PH-2305 125-84-8 AMINOGLUTETHIMIDE PH-0582A 317-34-0 AMINOPHYLLINE ANHYDROUS PH-1428B 19774-82-4 AMIODARONE HYDROCHLORIDE PH-1429B 549-18-8 AMITRIPTYLINE HYDROCHLORIDE PH-3019B 111470-99-6 AMLODIPINE BESYLATE PH-1431A 12125-02-9 AMMONIUM CHLORIDE (PHARM GRADE) PH-1431B 12125-02-9 AMMONIUM CHLORIDE (TECH GRADE) PH-5029 78613-38-4 AMOROLFINE HYDROCHLORIDE 78613-35-1 (BASE) PH-1932A 61336-70-7 AMOXYCILLIN TRIHYDRATE 26787-78-0 (BASE) PH-1433 1397-89-3 AMPHOTERICIN B PH-1720B 7177-48-2 AMPICILLIN TRIHYDRATE ® Copyright © 2013 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 3 of 38 Product Code CAS Product Name PH-2654A 121-25-5 AMPROLIUM PH-2654B 137-88-2 AMPROLIUM HYDROCHLORIDE PH-1906 60719-84-8 AMRINONE PH-1577 120511-73-1 ANASTROZOLE PH-0836C 532-11-6 ANETHOLE TRITHIONE PH-2925 72432-10-1 ANIRACETAM PH-2368 8007-70-3 ANISE OIL PH-4978 131707-23-8 ARBIDOL HYDROCHLORIDE PH-1440 53696-74-5 ARMILLARISIN-A PH-1441A 63968-64-9 ARTEMISININ PH-5230A 23964-58-1 ARTICAINE PH-5230B 23964-57-0 ARTICAINE HYDROCHLORIDE PH-1899AA 50-78-2 ASPIRIN PH-1899BA 62952-06-1 ASPIRIN DL-LYSINE PH-1443A 29122-68-7 ATENOLOL 93379-54-5 (S-ISOMER) 56715-13-0 (R-ISOMER) PH-4490B 134523-03-8 ATORVASTATIN CALCIUM PH-0812A 51-55-8 ATROPINE PH-0812AE 5908-99-6 ATROPINE SULFATE MONOHYDRATE MIS-3932 147403-03-0 AZILSARTAN MIS-3912 863031-21-4 AZILSARTAN MEDOXOMIL PH-3022A 83905-01-5 AZITHROMYCIN PH-3022B 117772-70-0 AZITHROMYCIN DIHYDRATE PH-2382B 37091-65-9 AZLOCILLIN SODIUM ® Copyright © 2013 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 4 of 38 Product Code CAS Product Name PH-1445A 1405-87-4 BACITRACIN PH-1445B 1405-89-6 BACITRACIN ZINC PH-4664B 150399-21-6 BALSALAZIDE DISODIUM SALT PH-4484B 81732-46-9 BAMBUTEROL HYDROCHLORIDE PH-5025B 82576-52-1 BENDAZAC LYSINE PH-0710 5003-48-5 BENORYLATE PH-1845B 19428-14-9 BENPROPERINE PHOSPHATE PH-0251AA 8043-47-8 BENZALKONIUM BROMIDE 91080-29-4 (C8-18) 7281-04-1 (C12) PH-4775 3562-84-3 BENZBROMARONE PH-0797B 52-49-3 BENZHEXOL HYDROCHLORIDE PH-0759 94-09-7 BENZOCAINE PH-1450A 5579-84-0 BETAHISTINE HYDROCHLORIDE PH-0953A 378-44-9 BETAMETHASONE PH-0953D 5593-20-4 BETAMETHASONE DIPROPIONATE PH-2971AB 8008-63-7 BILE EXTRACT (BOVINE) PH-2971AA 8008-63-7 BILE EXTRACT (PORCINE) PH-1453 635-65-4 BILIRUBIN PH-3352 155206-00-1 BIMATOPROST PH-2334 603-50-9 BISACODYL PH-1457AA 1304-85-4 BISMUTH SUBNITRATE 10361-46-3 ? PH-1457E 14882-18-9 BISMUTH SUBSALICYLATE CC-0293EC 1330-43-4 BORAX ANHYDROUS ® Copyright © 2013 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 5 of 38 Product Code CAS Product Name CC-0293EA 1303-96-4 BORAX DECAHYDRATE CC-0292AA 10043-35-3 BORIC ACID PH-5741B 70359-46-5 BRIMONIDINE TARTRATE PH-1635 138890-62-7 BRINZOLAMIDE PH-0630 496-67-3 BROMISOVAL 66101-52-8 ((+/-)-ISOMER) PH-1591EC 980-71-2 BROMPHENIRAMINE MALEATE 32865-01-3 ((+/-)-ISOMER) PH-3141 51333-22-3 BUDESONIDE PH-2698AB 35543-24-9 BUFLOMEDIL HYDROCHLORIDE PH-0860 28395-03-1 BUMETANIDE PH-1461C 2180-92-9 BUPIVACAINE PH-1461A 14252-80-3 BUPIVACAINE HYDROCHLORIDE PH-4780AB 31677-93-7 BUPROPION HYDROCHLORIDE PH-4392B 33386-08-2 BUSPIRONE HYDROCHLORIDE PH-0591A 58-08-2 CAFFEINE (NATURAL) PH-1462A 471-34-1 CALCIUM CARBONATE PH-4117G 86016-46-8 CALCIUM CHONDROITIN SULFATE PH-4638HA 5793-88-4 CALCIUM D-SACCHARATE PH-0451AC 1492-18-8 CALCIUM FOLINATE PH-1060BB 7789-77-7 CALCIUM HYDROGEN PHOSPHATE DIHYDRATE PH-5287 CAMELLIA OIL PH-1302AA 76-22-2 CAMPHOR (SYNTHETIC) PH-4829B 145040-37-5 CANDESARTAN CILEXETIL PH-1469 62571-86-2 CAPTOPRIL ® Copyright © 2013 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 6 of 38 Product Code CAS Product Name PH-0699 298-46-4 CARBAMAZEPINE PH-0870D 51460-26-5 CARBAZOCHROME SODIUM SULFONATE PH-1812B 38821-49-7 CARBIDOPA MONOHYDRATE PH-1490BA 41575-94-4 CARBOPLATIN PH-0791 78-44-4 CARISOPRODOL PH-0388 154-93-8 CARMUSTINE PH-4510 53716-49-7 CARPROFEN PH-4222 72956-09-3 CARVEDILOL CC-1273AA 8001-79-4 CASTOR OIL PH-2092 50370-12-2 CEFADROXIL 66592-87-8 (MONOHYDRATE) PH-4956 91832-40-5 CEFDINIR PH-5110AB 123171-59-5 CEFEPIME HYDROCHLORIDE PH-4088B 111696-23-2 CEFETAMET PIVOXIL HYDROCHLORIDE PH-3501 79350-37-1 CEFIXIME PH-4996B 86329-79-5 CEFODIZIME SODIUM PH-1234B 61270-78-8 CEFONICID DISODIUM PH-1830AB 64485-93-4 CEFOTAXIME SODIUM PH-2234A 66309-69-1 CEFOTIAM HYDROCHLORIDE PH-2101 33564-30-6 CEFOXITIN SODIUM PH-4955B 98753-19-6 CEFPIROME SULFATE PH-3659A 72558-82-8 CEFTAZIDIME PH-1666 41136-22-5 CEFTEZOLE SODIUM PH-4830A 80370-57-6 CEFTIOFUR ® Copyright © 2013 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 7 of 38 Product Code CAS Product Name PH-4830C 103980-44-5 CEFTIOFUR HYDROCHLORIDE PH-2009B 104376-79-6 CEFTRIAXONE SODIUM,HEMI(HEPTAHYDRATE) 74578-69-1 (ANHYDROUS) PH-3147B 56238-63-2 CEFUROXIME SODIUM PH-0144AC 23325-78-2 CEPHALEXIN MONOHYDRATE PH-0139B 58-71-9 CEPHALOTHIN SODIUM PH-2115 38821-53-3 CEPHRADINE PH-4223B 83881-52-1 CETIRIZINE HYDROCHLORIDE PH-4541A 123-03-5 CETYLPYRIDINIUM CHLORIDE, ANHYDROUS PH-0083A 56-75-7 CHLORAMPHENICOL PH-0083C 530-43-8 CHLORAMPHENICOL PALMITATE PH-0664A 57-15-8 CHLORBUTOL ANHYDROUS PH-0664B 6001-64-5 CHLORBUTOL HEMIHYDRATE 1320-66-7 ? PH-1106A 58-25-3 CHLORDIAZEPOXIDE BASE PH-0252B 56-95-1 CHLORHEXIDINE ACETATE 206986-79-0 (HYDRATE) PH-0252C 39014-05-6 CHLORHEXIDINE CITRATE PH-0252D 18472-51-0 CHLORHEXIDINE GLUCONATE PH-0252E 3697-42-5 CHLORHEXIDINE HYDROCHLORIDE PH-0762B 3858-89-7 CHLOROPROCAINE HYDROCHLORIDE PH-0298A 50-63-5 CHLOROQUINE PHOSPHATE PH-1630 58-94-6 CHLOROTHIAZIDE PH-1591BC 113-92-8 CHLORPHENIRAMINE MALEATE 7054-11-7 ((+/-)-CHLORPHENIRAMINE ISOMER) ® Copyright © 2013 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD.
Load more

Recommended publications
  • Comparative Evaluation of Dehydroepiandrosterone Sulfate
    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2016/12/01/dmd.116.072355.DC1 1521-009X/45/2/224–227$25.00 http://dx.doi.org/10.1124/dmd.116.072355 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 45:224–227, February 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics Short Communication Comparative Evaluation of Dehydroepiandrosterone Sulfate Potential to Predict Hepatic Organic Anion Transporting Polypeptide Transporter-Based Drug-Drug Interactions s Received July 4, 2016; accepted November 30, 2016 ABSTRACT Pharmacokinetic drug-drug interactions (DDIs) on hepatic organic 59 ml/rat. Comparison of the in vitro IC50 of rifampicin for DHEAS anion transporting polypeptides (OATPs) are important clinical issues. uptake by isolated rat hepatocytes and in vivo plasma rifampicin Previously, we reported that plasma dehydroepiandrosterone sulfate concentration suggested that the effect of rifampicin on the plasma Downloaded from (DHEAS) could serve as an endogenous probe to predict OATP-based DHEAS concentration was explained mostly by the inhibition of DDIs in monkeys using rifampicin as an OATP inhibitor. Since the hepatic OATPs, demonstrating that DHEAS could be a biomarker of contribution of hepatic OATPs to the changes in plasma DHEAS by hepatic OATP activity. Next, previously reported rifampicin-induced rifampicin remains unclear, however, we performed an in vivo phar- changes in plasma concentrations evaluated as an AUC ratio (AUCR) macokinetic study to explore this issue. Since plasma DHEAS of possible probe compounds were compared on the basis of concentrations were low in our rat model, the disposition of externally rifampicin dose/body surface area.
    [Show full text]
  • ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential
    pharmaceuticals Review ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential Subrata Deb * , Anthony Allen Reeves, Robert Hopefl and Rebecca Bejusca Department of Pharmaceutical Sciences, College of Pharmacy, Larkin University, Miami, FL 33169, USA; [email protected] (A.A.R.); [email protected] (R.H.); [email protected] (R.B.) * Correspondence: [email protected]; Tel.: +224-310-7870 Abstract: On 11 March 2020, the World Health Organization (WHO) classified the Coronavirus Disease 2019 (COVID-19) as a global pandemic, which tested healthcare systems, administrations, and treatment ingenuity across the world. COVID-19 is caused by the novel beta coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Since the inception of the pandemic, treatment options have been either limited or ineffective. Remdesivir, a drug originally designed to be used for Ebola virus, has antiviral activity against SARS-CoV-2 and has been included in the COVID-19 treatment regimens. Remdesivir is an adenosine nucleotide analog prodrug that is metabolically activated to a nucleoside triphosphate metabolite (GS-443902). The active nucleoside triphosphate metabolite is incorporated into the SARS-CoV-2 RNA viral chains, preventing its replication. The lack of reported drug development and characterization studies with remdesivir in public domain has created a void where information on the absorption, distribution, metabolism, elimination (ADME) properties, pharmacokinetics (PK), or drug-drug interaction (DDI) is limited. By Citation: Deb, S.; Reeves, A.A.; understanding these properties, clinicians can prevent subtherapeutic and supratherapeutic levels of Hopefl, R.; Bejusca, R. ADME and remdesivir and thus avoid further complications in COVID-19 patients. Remdesivir is metabolized Pharmacokinetic Properties of by both cytochrome P450 (CYP) and non-CYP enzymes such as carboxylesterases.
    [Show full text]
  • Sodium Prasterone Sulfate Hydrate Sodium Pyrosulfite
    JP XVI Official Monographs / Sodium Pyrosulfite 1411 50 mL. Perform the test using this solution as the test solu- Sodium Prasterone Sulfate Hydrate tion. Prepare the control solution as follows: to 0.40 mL of 0.005 mol/L sulfuric acid VS add 20 mL of acetone, 1 mL of プラステロン硫酸エステルナトリウム水和物 dilute hydrochloric acid and water to make 50 mL (not more than 0.032z). (4) Heavy metals <1.07>—Proceed with 2.0 g of Sodium Prasterone Sulfate Hydrate according to Method 2, and per- form the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm). (5) Related substances—Dissolve 0.10 g of Sodium Prasterone Sulfate Hydrate in 10 mL of methanol, and use C19H27NaO5S.2H2O: 426.50 this solution as the sample solution. Pipet 1 mL of the sam- Monosodium 17-oxoandrost-5-en-3b-yl sulfate dihydrate ple solution, add methanol to make exactly 200 mL, and use [1099-87-2, anhydride] this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatogra- Sodium Prasterone Sulfate Hydrate contains not phy <2.03>. Spot 5 mL each of the sample solution and stand- less than 98.0z of sodium prasterone sulfate ard solution on a plate of silica gel with fluorescent indicator (C19H27NaO5S: 390.47), calculated on the dried basis. for thin-layer chromatography. Develop the plate with a mixture of chloroform, methanol and water (75:22:3) to a Description Sodium Prasterone Sulfate Hydrate occurs as distance of about 10 cm, and air-dry the plate.
    [Show full text]
  • Reproductive DHEA-S
    Reproductive DHEA-S Analyte Information - 1 - DHEA-S Introduction DHEA-S, DHEA sulfate or dehydroepiandrosterone sulfate, it is a metabolite of dehydroepiandrosterone (DHEA) resulting from the addition of a sulfate group. It is the sulfate form of aromatic C19 steroid with 10,13-dimethyl, 3-hydroxy group and 17-ketone. Its chemical name is 3β-hydroxy-5-androsten-17-one sulfate, its summary formula is C19H28O5S and its molecular weight (Mr) is 368.5 Da. The structural formula of DHEA-S is shown in (Fig.1). Fig.1: Structural formula of DHEA-S Other names used for DHEA-S include: Dehydroisoandrosterone sulfate, (3beta)-3- (sulfooxy), androst-5-en-17-one, 3beta-hydroxy-androst-5-en-17-one hydrogen sulfate, Prasterone sulfate and so on. As DHEA-S is very closely connected with DHEA, both hormones are mentioned together in the following text. Biosynthesis DHEA-S is the major C19 steroid and is a precursor in testosterone and estrogen biosynthesis. DHEA-S originates almost exclusively in the zona reticularis of the adrenal cortex (Fig.2). Some may be produced by the testes, none is produced by the ovaries. The adrenal gland is the sole source of this steroid in women, whereas in men the testes secrete 5% of DHEA-S and 10 – 20% of DHEA. The production of DHEA-S and DHEA is regulated by adrenocorticotropin (ACTH). Corticotropin-releasing hormone (CRH) and, to a lesser extent, arginine vasopressin (AVP) stimulate the release of adrenocorticotropin (ACTH) from the anterior pituitary gland (Fig.3). In turn, ACTH stimulates the adrenal cortex to secrete DHEA and DHEA-S, in addition to cortisol.
    [Show full text]
  • Tuesday June 2 Wednesday June 3
    Tuesday June 2 14:00- Registration 18:30 19:30 Welcome reception Wednesday June 3 08:00- Registration 09:00 09:00- Welcome and Introduction 09:15 09:15- Targeting Ebola Chair: Steven Kern 10:45 09:15- Conducting clinical trials in challenging Steven Kern 09:30 environments 09:30- France Estimating an effective dose for a repurposed 09:55 Mentré drug to treat Ebola: the case of favipiravir Estimating an effective dose for a new drug to 09:55- Matthias treat Ebola with incomplete information: the 10:20 Machacek case of Zmapp 10:20- An Adaptive Platform Trial for Ebola: Scott Berry 10:45 Application to Future Epidemics 10:45- Coffee break, Poster and Software session I 12:15 Posters in Group I (with poster numbers starting with I-) are accompanied by their presenter 12:15- Diabetes Chair: IñakiTrocóniz 12:55 Page | 1 12:15- Roberto A model of glucose clearance to improve the 12:35 Bizzotto description of glucose homeostasis A longitudinal HbA1c model elucidates genes 12:35- Rada Savic linked to disease progression on metformin 12:55 therapy 12:55- Lunch 14:25 On the 20th anniversary of 'Nonlinear 14:25- Chair: France models for repeated measurement 15:15 Mentré data' 14:25- David Why write a book in 1995 on nonlinear mixed 14:50 Giltinan effects modeling? 14:50- Marie Subsequent developments in nonlinear mixed 15:15 Davidian effects modeling 15:15- Tea break, Poster and Software session II 16:40 Posters in Group II (with poster numbers starting with II-) are accompanied by their presenter 16:40- Other diseases Chair: Ana Ruiz 17:40 José
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • Drug-Excipient Interaction and Its Importance in Dosage Form
    Journal of Applied Pharmaceutical Science 01 (06); 2011: 66-71 ISSN: 2231-3354 Drug-excipient interacti on and its importance in Received: 29-07-2011 Revised on: 02-08-2011 Accepted: 04-08-2011 dosage form development Nishath Fathima, Tirunagari Mamatha, Husna Kanwal Qureshi, Nandagopal Anitha and Jangala Venkateswara Rao ABSTRACT Excipients are included in dosage forms to aid manufacture, administration or absorption. Although considered pharmacologically inert, excipients can initiate, propagate or participate in Nishath Fathima, Tirunagari chemical or physical interactions with drug compounds, which may compromise the effectiveness Mamatha, Husna Kanwal Qureshi, of a medication. Exicipients are not exquisitely pure. Even for the most commonly used excipients, Nandagopal Anitha and Jangala it is necessary to understand the context of their manufacture in order to identify potential active pharmaceutical ingredients interactions with trace components. Chemical interactions can lead to Venkateswara Rao Sultan-Ul-Uloom College of Pharmacy, degradation of the active ingredient, thereby reducing the amount available for therapeutic effect. Physical interactions can affect rate of dissolution, uniformity of dose or ease of administration. Banjara Hills, Hyderabad - 500034, A.P., India. Key words: Excipient, Drug, Interaction, Physical, Chemical. INTRODUCTION Pharmaceutical dosage form is a combination of active pharmaceutical ingredients (API) and excipients. Excipients are included in dosage forms to aid manufacture, administration or absorption (Crowley and Martini).The ideal excipients must be able to fulfill the important functions i.e. dose, stability and release of API from the formulation. Although considered pharmacologically inert, excipients can initiate, propagate or participate in chemical or physical interactions with drug compounds, which may compromise the effectiveness of a medication.
    [Show full text]
  • Current Therapeutic Applications and Pharmacokinetic Modulations of Ivermectin
    Veterinary World, EISSN: 2231-0916 REVIEW ARTICLE Available at www.veterinaryworld.org/Vol.12/August-2019/5.pdf Open Access Current therapeutic applications and pharmacokinetic modulations of ivermectin Khan Sharun1, T. S. Shyamkumar2, V. A. Aneesha2, Kuldeep Dhama3, Abhijit Motiram Pawde1 and Amar Pal1 1. Division of Surgery, ICAR-Indian Veterinary Research Institute, Bareilly, Uttar Pradesh, India; 2. Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Bareilly, Uttar Pradesh, India; 3. Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, Uttar Pradesh, India. Corresponding author: Khan Sharun, e-mail: [email protected] Co-authors: TSS: [email protected], VAA: [email protected], KD: [email protected], AMP: [email protected], AP: [email protected] Received: 17-05-2019, Accepted: 29-06-2019, Published online: 08-08-2019 doi: 10.14202/vetworld.2019.1204-1211 How to cite this article: Sharun K, Shyamkumar TS, Aneesha VA, Dhama K, Pawde AM, Pal A (2019) Current therapeutic applications and pharmacokinetic modulations of ivermectin, Veterinary World, 12(8): 1204-1211. Abstract Ivermectin is considered to be a wonder drug due to its broad-spectrum antiparasitic activity against both ectoparasites and endoparasites (under class of endectocide) and has multiple applications in both veterinary and human medicine. In particular, ivermectin is commonly used in the treatment of different kinds of infections and infestations. By altering the vehicles used in the formulations, the pharmacokinetic properties of different ivermectin preparations can be altered. Since its development, various vehicles have been evaluated to assess the efficacy, safety, and therapeutic systemic concentrations of ivermectin in different species. A subcutaneous route of administration is preferred over a topical or an oral route for ivermectin due to superior bioavailability.
    [Show full text]
  • Parasitology Group Annual Review of Literature and Horizon Scanning Report 2018
    APHA Parasitology Group Annual Review of Literature and Horizon Scanning Report 2018 Published: November 2019 November 2019 © Crown copyright 2018 You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v.3. To view this licence visit www.nationalarchives.gov.uk/doc/open-government-licence/version/3/ or email [email protected] This publication is available at www.gov.uk/government/publications Any enquiries regarding this publication should be sent to us at [email protected] Year of publication: 2019 The Animal and Plant Health Agency (APHA) is an executive agency of the Department for Environment, Food & Rural Affairs, and also works on behalf of the Scottish Government and Welsh Government. November 2019 Contents Summary ............................................................................................................................. 1 Fasciola hepatica ............................................................................................................. 1 Rumen fluke (Calicophoron daubneyi) ............................................................................. 2 Parasitic gastro-enteritis (PGE) ........................................................................................ 2 Anthelmintic resistance .................................................................................................... 4 Cestodes .........................................................................................................................
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • APHA Parasitology Group: Annual Review of Literature and Horizon Scanning Report 2018
    APHA Parasitology Group Annual Review of Literature and Horizon Scanning Report 2018 Published: November 2019 November 2019 © Crown copyright 2019 You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v.3. To view this licence visit www.nationalarchives.gov.uk/doc/open-government-licence/version/3/ or email [email protected] This publication is available at www.gov.uk/government/publications Any enquiries regarding this publication should be sent to us at [email protected] Year of publication: 2019 The Animal and Plant Health Agency (APHA) is an executive agency of the Department for Environment, Food & Rural Affairs, and also works on behalf of the Scottish Government and Welsh Government. October 2018 Contents Summary ............................................................................................................................. 1 Fasciola hepatica ............................................................................................................. 1 Rumen fluke (Calicophoron daubneyi) ............................................................................. 2 Parasitic gastro-enteritis (PGE) ........................................................................................ 2 Anthelmintic resistance .................................................................................................... 4 Cestodes .........................................................................................................................
    [Show full text]
  • The New Anthelmintic Tribendimidine Is an L-Type (Levamisole and Pyrantel) Nicotinic Acetylcholine Receptor Agonist
    The New Anthelmintic Tribendimidine is an L-type (Levamisole and Pyrantel) Nicotinic Acetylcholine Receptor Agonist Yan Hu1, Shu-Hua Xiao2, Raffi V. Aroian1* 1 Section of Cell and Developmental Biology, University of California, San Diego, La Jolla, California, United States of America, 2 National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, People’s Republic of China Abstract Background: Intestinal parasitic nematodes such as hookworms, Ascaris lumbricoides, and Trichuris trichiura are amongst most prevalent tropical parasites in the world today. Although these parasites cause a tremendous disease burden, we have very few anthelmintic drugs with which to treat them. In the past three decades only one new anthelmintic, tribendimidine, has been developed and taken into human clinical trials. Studies show that tribendimidine is safe and has good clinical activity against Ascaris and hookworms. However, little is known about its mechanism of action and potential resistance pathway(s). Such information is important for preventing, detecting, and managing resistance, for safety considerations, and for knowing how to combine tribendimidine with other anthelmintics. Methodology/Principal Findings: To investigate how tribendimidine works and how resistance to it might develop, we turned to the genetically tractable nematode, Caenorhabditis elegans. When exposed to tribendimidine, C. elegans hermaphrodites undergo a near immediate loss of motility; longer exposure results in extensive body damage, developmental arrest, reductions in fecundity, and/or death. We performed a forward genetic screen for tribendimidine- resistant mutants and obtained ten resistant alleles that fall into four complementation groups. Intoxication assays, complementation tests, genetic mapping experiments, and sequencing of nucleic acids indicate tribendimidine-resistant mutants are resistant also to levamisole and pyrantel and alter the same genes that mutate to levamisole resistance.
    [Show full text]